Abaloparatide

Bone formation

US Tymlos is approved for postmenopausal women with osteoporosis at high fracture risk. A separate US indication covers increasing bone density in men with osteoporosis at high fracture risk. The men’s trial did not establish fracture reduction.²³⁹

How it works

Abaloparatide is a synthetic 34-amino-acid analogue of parathyroid hormone-related protein, or PTHrP. It activates the PTH1 receptor. Its effects on bone formation and bone resorption depend on the pattern of exposure; it is not a general-purpose tissue-repair peptide.²³⁹

Fewer spine fractures

The ACTIVE trial studied postmenopausal women with osteoporosis. The meaning of its numbers depends on which outcome and analysis population you use.

0.6% vs 4.2%

Over 18 months, new vertebral fractures occurred in 0.6% of 690 women assigned to abaloparatide versus 4.2% of 711 assigned to placebo among those with the required spine images. The study used 80 micrograms subcutaneously each day. These are studied conditions, not a personal treatment plan.²³⁹

Why the European figures differ

EMA excluded two trial sites after serious study-conduct findings, reducing the original randomized population from 2,463 to 2,070. Its spine-fracture analysis found 3 events among 583 women receiving abaloparatide and 25 among 600 receiving placebo. The result remained statistically significant.^241,242

Analysis	Reported result at 19 months
US label	2.7% with abaloparatide versus 4.7% with placebo; p=0.049.239
EMA, excluding two sites	2.7% versus 3.6%; hazard ratio 0.74 (95% CI 0.38 to 1.43), p=0.3675. Not statistically significant.242,241

Is it better than teriparatide?

The teriparatide comparison was open label. Whether abaloparatide prevents more fractures than teriparatide remains unclear.²⁴¹

Men and treatment follow-up

The men's trial measured bone density; follow-up in women included additional osteoporosis treatment.

228 men

The US trial randomized 228 men, 149 to abaloparatide and 79 to placebo. At 12 months, lumbar-spine bone density increased by 8.5% versus 1.2% in the label’s rounded figures. The primary endpoint was bone density, not fracture reduction.²³⁹

After abaloparatide

ACTIVExtend followed eligible women from ACTIVE while they received alendronate. The US label describes 1,139 participants; the EMA analysis excludes the same problematic sites and includes 963. Participants were not newly randomized to alendronate.^239,241

Transdermal comparison

In a randomized trial of 511 postmenopausal women with osteoporosis, spine bone density rose 7.14% with the transdermal system versus 10.86% with the injection at 12 months. The patch failed its prespecified non-inferiority comparison. The company subsequently reported ending its transdermal work in June 2022.^251,240,243

Does it help a fracture heal?

The fracture-prevention study and the pelvic-healing trial measured different outcomes.

48 people

A 2026 trial enrolled postmenopausal women and men aged at least 50 within four weeks of a pelvic fracture. At three months, abaloparatide did not significantly improve CT-measured healing, physical performance or change in pain compared with placebo.²⁵²

Why the result has limits

The participants had a mean age of 82, and 93% were women. The trial was small. This trial found no improvement in pelvic-fracture healing.²⁵²

A knee-replacement study measured something else

An observational study included 58 people undergoing total knee replacement. Treated patients had osteoporosis, while untreated controls had osteopenia without fracture. Bone-density differences around the knee are interesting, but those unequal groups and imaging outcomes do not establish better implant survival or faster healing.²⁵³

Safety and monitoring

Approved use comes with warnings, monitoring and limits on who was studied.

Serious allergy

The August 2026 US label adds a dedicated warning for hypersensitivity, including anaphylaxis, angioedema and urticaria. An older safety summary may miss this update.^239,244

Dizziness and heart symptoms

Dizziness, nausea and palpitations are reported adverse effects. The labels describe orthostatic symptoms and temporary increases in heart rate. European information calls for assessment of blood pressure, cardiac status and ECG before treatment.^239,242

Calcium and kidney function

The labels warn about raised blood calcium and urine calcium. US information allows use without dose adjustment in severe kidney impairment but calls for monitoring because exposure rises; European information contraindicates severe kidney impairment. These are different regional prescribing rules.^239,242

The cancer warning needs context

Abaloparatide caused bone tumors in rats. Human risk remains unknown. The US boxed warning was removed in December 2021, but the ordinary osteosarcoma warning remained; removal of the box did not remove the underlying concern.^239,245

Long-term uncertainty

The current US label says observational studies of PTH analogues have not shown increased osteosarcoma risk. That class-level finding does not prove an abaloparatide-specific lifetime risk of zero. A registered European comparative cardiovascular safety study remains in planned status.^239,246

The country changes the label

A label from one country sets its indications, treatment limits and precautions.

Question	What the labels say
Who is it for?	US: high-risk postmenopausal women, plus a separate bone-density indication in high-risk men. EU: postmenopausal women at increased fracture risk.239,242
How long?	US: use beyond two years during a lifetime is not recommended. EU: maximum total treatment duration is 18 months.239,242
Severe kidney impairment?	US: no dose adjustment, with monitoring for adverse effects. EU: contraindicated, including end-stage renal disease.239,242

Other country approvals

UK product information also gives an 18-month maximum. Swissmedic records approval for postmenopausal women at high fracture risk. The dated Australian PI attachment describes postmenopausal women and 18 months, but it warns that a later version may supersede it.^248,249,250

Common questions

Comparisons, side effects, treatment length and the questions people ask before and during treatment.

01 How does abaloparatide compare with Forteo, Evenity, Prolia, or bisphosphonates?

Direct comparisons are narrower than the brand list suggests. A 2026 matched observational cohort compared abaloparatide with romosozumab for 12-month BMD and hip structure, while a 222-person phase 2 study and ACTIVE included teriparatide arms; none of those comparisons established comparative fracture benefit across all options. Claims-data comparisons with teriparatide and the alendronate follow-on sequence add context, but they do not establish one best medicine across all outcomes or patients.^{254,255,241,256,257,258}

02 Which side effects were common, and which warnings are more serious?

In the women's trial, the US label reports dizziness in 10% versus 6% with placebo, nausea 8% versus 3%, headache 8% versus 6%, and palpitations 5% versus 0.4%; 10% versus 6% stopped study drug because of adverse events. The label separately warns about severe hypersensitivity, osteosarcoma uncertainty, orthostatic symptoms, hypercalcemia, hypercalciuria, and possible stone concerns. FDA approved strengthened hypersensitivity wording on August 3, 2026.^239,244

03 What does the label say about the pen, storage, travel, and missed doses?

The US label describes a ready-to-use prefilled pen with separate storage conditions before first use and during its 30-day in-use period. It does not provide a generic restart rule for an interruption, and travel handling is product-specific rather than based on investigational transdermal systems or unverified vials. Instructions for a particular pen and missed dose come from its label, pharmacist or prescriber.^239,259,251

04 Where is abaloparatide authorized, and what do current official records show about cost, insurance, or a generic?

As of September 30, 2026, official records confirm US TYMLOS approval, EU Eladynos product information, and a current Japanese Ostabalo product record. Those records do not establish a current worldwide market map, out-of-pocket price, plan coverage, prior-authorization result, or generic availability. Prices and coverage depend on dated jurisdiction, product, pharmacy and insurance records.^260,242,261

05 How long is treatment used, and what happened after abaloparatide stopped?

The current US label says safety and efficacy beyond two years have not been evaluated and recommends against more than two years during a lifetime; the EU SmPC sets a maximum total duration of 18 months. ACTIVExtend then offered eligible ACTIVE completers open-label alendronate, and the sequence retained a lower incidence of new spine fractures, reported as radiographic vertebral fractures, than placebo followed by alendronate. That extension does not show what happens with no follow-on osteoporosis treatment.^{239,242,257,241}

06 What does the label say about dose timing, daily use, and interruptions?

The US label states an 80 microgram subcutaneous dose once daily and describes initial doses where the patient can sit or lie down if orthostatic symptoms occur. It does not supply a universal clock time, cycle, taper, catch-up method, or restart rule. This is a description of the current product label, not a self-directed schedule.²³⁹

07 Does the rat osteosarcoma finding mean abaloparatide causes bone cancer in people?

No causal human conclusion follows from the rat result. The current US label says rats developed dose-dependent tumors at exposures 4 to 28 times clinical exposure, human risk is unknown, and observational studies of PTH analogues have not shown increased risk. That class-level observation is reassuring but does not prove an abaloparatide-specific long-term risk of zero, especially beyond two years.²³⁹

08 How much did bone density change, and when can an individual know whether it worked?

Group averages differed by study: ACTIVE reported 18-month BMD changes in postmenopausal women, ATOM reported 12-month changes in men, and ACTIVE-J reported 78-week BMD changes in Japanese women and men. A DXA change is not the same endpoint as avoiding a fracture, and individual scans can differ from trial means. These studies do not establish one response date that applies to everyone or guarantee improvement at every skeletal site.^{255,262,263,239}

09 Who was actually studied and approved, including men, women, pregnancy, and younger people?

The current US label covers postmenopausal women at high fracture risk and separately men for increasing BMD at high fracture risk; the EU indication is for postmenopausal women. TYMLOS is not indicated for females of reproductive potential, has no human pregnancy data in the label, and has no established pediatric safety or effectiveness. ACTIVE, ATOM, and ACTIVE-J answer different population and endpoint questions and should not be pooled into one universal claim.^{239,242,255,262,263}

10 What do the evidence and labels say about calcium, kidney stones, and renal impairment?

The US label warns about hypercalcemia and hypercalciuria and says it is unknown whether active or prior urolithiasis may worsen; suspected cases may prompt urine-calcium assessment by the treating clinician. Its single-dose renal study found higher exposure in severe impairment and says no dose adjustment but adverse-reaction monitoring, while the EU SmPC contraindicates severe renal impairment. The ACTIVE renal subgroup excluded important severe-impairment patients, so it cannot erase that jurisdictional difference.^239,242,264

11 Can abaloparatide cause palpitations, a fast heart rate, dizziness, or low blood pressure?

Yes, transient post-dose symptoms are part of the current label. In ACTIVE, heart rate rose and blood pressure fell slightly after dosing; serious cardiac adverse-event percentages were similar across groups, but those analyses do not prove zero long-term cardiovascular risk. The EU SmPC adds cardiac assessment and monitoring language that is not identical to the US label.^239,265,242

12 Does abaloparatide help fracture healing, dental work, implants, or orthopedic surgery?

The strongest located healing trial was a 48-person randomized pelvic-fracture study, and it found no significant difference in CT healing, physical performance, or pain change at three months. A separate 58-person open-label observational TKA study reported distal-femur BMD differences, but the treated and control groups differed at baseline and it did not establish general surgical healing. The source search located no human dental or implant treatment study that established benefit.^252,253

13 What is abaloparatide, and how does it build bone?

Abaloparatide is a synthetic 34-residue PTHrP(1-34) analogue that activates the PTH1 receptor. The label describes increased bone formation on trabecular and cortical surfaces, and GSRS records an Aib residue at position 29 plus C-terminal amidation. This adult bone-remodeling mechanism does not itself establish fracture healing, height gain, or benefit outside the studied osteoporosis populations.^239,266

14 Can abaloparatide make an adult taller or reopen growth plates?

The cited human treatment trials and current labels do not support adult height gain or reopening a mature growth plate. ACTIVE measured fractures and BMD in postmenopausal women, while ATOM measured BMD in men. The label places open epiphyses in its osteosarcoma-risk precautions and does not list them as a growth indication.^239,255,262

15 Why do spine (vertebral) and non-spine fracture numbers differ across the US and European records?

Why the numbers differ: spine, also called vertebral, and non-spine fracture results use different outcome definitions, observation windows, and analyzed populations from the same ACTIVE trial. The US label keeps the original analysis and reports 2.7% versus 4.7% Kaplan-Meier nonvertebral estimates at 19 months, while EMA excluded two sites for serious GCP findings and reports 2.7% versus 3.6%, hazard ratio 0.74 with p=0.3675. EMA raw event proportions, 15 of 696 versus 21 of 688, are not interchangeable with those Kaplan-Meier estimates.^{239,255,241,242}